Agfa-Gevaert Group in Q3 2023: Overall EBITDA Growth Driven by Strong PerformanceNovember 20, 2023 | Agfa-Gevaert
Estimated reading time: 3 minutes
Agfa-Gevaert commented on its results in the third quarter of 2023.
“I am pleased to see that all growth engines performed well, even in the face of challenging economic and geopolitical conditions as well as adverse currency effects. We considerably improved the profitability of the Digital Print activities and the HealthCare IT division. Sales for our ZIRFON membranes for green hydrogen production continued to grow strongly and this business also started to contribute to profitability. On the back of good operational performance, we have returned to a positive free cash flow in the third quarter,” said Pascal Juéry, President and CEO of the Agfa-Gevaert Group.
Reporting post Offset Solutions
The recent sale of the Offset Solutions division (now rebranded to ECO3) influences the way the Agfa-Gevaert Group reports its results. The numbers from sales to EBITDA present the Agfa-Gevaert Group with Offset Solutions excluded, but with a new division called ‘Contractor Operations & Services former Offset’ or ‘CONOPS’. CONOPS represents the supply of film and chemicals as well as a set of support services delivered by Agfa to the external party ECO3. The turnover represents the supply agreements, with corresponding COGS charges. The income related to the support services will be accounted for as Other Income, while the costs related to those support services are re-presented in the different SG&A lines. The comparative period Q3 ‘22 has been re-presented accordingly. As per IFRS 5, stranded costs related to Offset Solutions have been treated differently in 2023 vs 2022. In Q3 ‘22 stranded costs are reported under CONOPS. In Q3 ‘23 these are absorbed by the three business divisions.
- Excluding currency effects, the Agfa-Gevaert Group’s revenue increased by 1.3% versus the third quarter of 2022, driven by the HealthCare IT division, ZIRFON membranes for green hydrogen production and the good performance of the ink product lines in the Digital Print & Chemicals division. Traditional film activities were under pressure from challenging economic conditions (including adverse currency effects and the weakening economy in China) and the current geopolitical circumstances.
- Driven by the HealthCare IT and Digital Print & Chemicals divisions, the Group’s gross profit margin improved to 30.5%, in spite of adverse effects including cost inflation, adverse currency effects, manufacturing inefficiencies and the weakness in the industrial film markets.
- Adjusted EBITDA improved strongly from 7 million Euro to 17 million Euro (6.1% of revenue).
- Restructuring and non-recurring items resulted in a charge of 5 million Euro versus 12 million Euro in Q3 2022.
- The net finance costs amounted to 7 million Euro.
- Income tax expenses increased to 6 million Euro versus 5 million Euro in Q3 2022.
- The Agfa-Gevaert Group posted a net loss of 15 million Euro.
Financial position and cash flow
- Net financial debt (including IFRS 16) remained stable versus Q2 2023 at 33 million Euro.
- Trade working capital (CONOPS excluded) evolved from 35% of turnover at the end of Q3 2022 to 31% in Q3 2023. In absolute numbers, trade working capital evolved from 370 million Euro at the end of Q3 2022 to 341 million Euro.
- In Q3 2023, the Group generated a free cash flow of 5 million Euro.
The Agfa-Gevaert Group confirms the outlook that was provided in the Q2 2023 press release. Overall, the Agfa-Gevaert Group expects a recovery in profitability in the full year 2023 versus 2022.
2023 outlook per division:
- HealthCare IT: Order intake growth continues to be strong. As the portion of own IP in the sales mix is expected to grow, profitability is expected to continue to improve versus the third quarter. This will likely result in a strong end of the year. Impacted by adverse currency effects, full year EBITDA is expected to be slightly below that of last year.
- Radiology Solutions: For medical film, exchange rate and margin pressure is expected to continue, resulting in a weak performance in the fourth quarter. The progress in Direct Radiography is expected to continue.
- Digital Print & Chemicals: The division expects to continue to improve profitability, based on pricing, cost improvement actions and positive contributions from digital print and the ZIRFON membranes. The revenue generated by ZIRFON will continue to grow very strongly.
Real Time with... productronica 2023: Alltemated's Patented Adhesive Improves Solder Joint Reliability12/06/2023 | Real Time with...productronica
Randy Temple, from Alltemated explains how his company’s Place-n-bond™ underfilm is applied at pick and place. The product is made of thermoplastic which means it is 100% reworkable.
Michael Hanke shares key features of Rehm’s latest energy-efficient reflow soldering equipment. He and Pete Starkey also discuss the company’s complete line of integrated solutions.
As part of the Peters Coating Innovation Forum (PCIF), Peters presented the new MYC50 coating machine in the showroom.
Lino Souza outlines how Pluritec has automated the nine steps of lamination in a continuous Pluritec line, resulting in process times as much as 33% of traditional manual methods, all with increased accuracy and quality. Souza states that, if you do 50-75 panels a day or more, the ROI will pay for itself through saved labor alone.
Real Time with... productronica 2023: BTU's Bob Bouchard Discusses Latest Reflow Soldering Technology12/05/2023 | Real Time with...productronica
In this interview, Pete Starkey meets with Bob Bouchard from BTU. With its ability to handle high volume, BTU's Aurora reflow soldering system helps reduce downtime, saves energy, has improved accessibility, and more.